



ECOBALTIC
BUSINESS PARK



Project
presentation

OITMENT MANUFACTURING

ECOBALTIC industrial business park
Bagrationovsky city district
Kaliningrad Region

2018



INVESTMENT IDEA

Creation of the production of ointment forms of pharmaceutical products (first stage: Inflammistin®, Miramistin®).



IMPORTANCE

Despite the wide availability of health aids for the topical treatment of septic wounds, the desired wound healing effect had not been achieved. Hence, the new, highly efficient combined product Inflammistin® has been developed.

Miramistin® is another successful project of the INFAMED and it is also planned for release in the ointment form 0,5%. It is aimed at prevention of the drug resistance development and side effects, by contrast with other products containing antibiotics and corticosteroids. The steady growth of this group of pharmaceutical products in monetary terms is expected in the nearest future.



OBJECTIVE

Creation of the domestic manufacturing of the high-quality pharmaceutical products for the national market that will be able to replace the foreign counterparts partially, with the perspective of further export to the international markets.



GOALS

1. Launch of the production of a new pharmaceutical product Inflammistin®.
2. Increase in the production output of the pharmaceutical product Miramistin® through introduction of a new pharmaceutical form: an ointment for topical and outward application.
3. Achievement of a positive socio-economic effect by means of creation of new high-performance jobs in the region.
4. Increase in the amount of tax liabilities to the budgets of all levels.



INITIATOR
OF THE
PROJECT

INFAMED K LLC



LOCATION

ECOBALTIC industrial business park,
Bagrationovsky city district,
Kaliningrad Region



IMPLEMENTATION
PERIOD

II quarter 2020



Amount of investment

approx. \$2,3M

Production output

10 mln un./year

New jobs

30

Production area

1 500 m²

Implementation period

II quarter 2020



INFAMED K LLC.

The INFAMED K pharmaceutical plant, functioning since 2014, is the first pharmaceutical enterprise in the Kaliningrad Region that produces the innovative popular antiseptic product Miramistin® 0,01% solution and Okomistin® eye drops, with the production output of up to 32 mln units a year. Countries of presence: Russia, Ukraine, Belarus, Kazakhstan, Kyrgyzstan, Armenia, Turkmenistan, Georgia, Uzbekistan.

Currently, the company is preparing for registration in China and the EU countries.



INFAMED



The revenue comprised 1,8 bn rubles in 2016.

The company plans to create a medical cluster specializing on the production of pharmaceuticals and medical products on the basis of the Ecobaltic industrial business park. In addition to the ointment workshop construction, there are plans of manufacturing modern urological Foley catheters (with the foreign participation), sprayers for pharmaceutical products and cosmetics, medical injection needles, polymeric medical packaging, etc. All projects are expected to have an import substitution effect for the Russian health care field.



INFLAMISTIN®, ointment for topical and outward application.

Pharmacological group: antiseptic product, enhancer of tissue regeneration, topical anesthetic.

The drug features a wide spectrum of antimicrobial effects, including hospital strains resistant to antibiotics. It could be used against combined infections, especially in the early stage of treatment before the pathogen's sensitivity is identified and determined.

Production form: 15 g or 30 g, released in aluminum tubes.



MIRAMISTIN®, ointment for topical and outward application.

Pharmacological group: antiseptic product.

Production form: 15 g or 30 g, released in aluminum tubes.

Demand in the Russian market

The market of pharmaceutical products for treating infected dermatoses is basically formed by the products of antimicrobial and anti-inflammatory action for outward application, which are produced in various pharmaceutical forms. Currently, these drugs include active components, which mostly contain antibiotics of different groups and corticosteroids that may cause the emergence of drug resistance of pathogens and lead to the development of side effects. Therefore a decision was made to conduct research in order to bring a highly effective pharmaceutical product to the market, the product that will exclude these drawbacks. This product is a 0.5% ointment for topical and outward application, Miramistin®.



10 QUALITIES OF MIRAMISTIN®

which make it one of the most effective antiseptic product

1. Miramistin® is an antiseptic product of a broad antimicrobial spectrum that has the following effects:
 - bactericide (Staphylococcus, Pseudomonas, Klebsiella, Proteus, Escherichia coli, etc.)
 - antiviral (varicella-zoster virus, influenza virus, adenovirus, labial and genital herpes virus type 1 and type 2, measles virus);
 - antifungal (yeast and yeast-like fungi (Candida, Penicillium, Aspergillus), dermatophytes);
 - active against sexually transmitted infections: gonorrhea, chlamydia, syphilis, trichomonas
2. It is not absorbed into the blood, does not have mutagenic, embryotoxic and carcinogenic effects.
3. It is not able to affect the developing fetus or be excreted with milk, in connection with which it can be prescribed to pregnant women.
4. Virtually eliminates side effects and the risk of allergic reactions.
5. Strengthens the effect of antibiotics, only affects pathogens and does not affect the composition of normal human microflora.
6. Has immunomodulatory and anti-inflammatory action.
7. Accelerates the regeneration of damaged skin and mucous membranes.
8. It prolongs the duration of remission and reduces the frequency of recurrences of chronic processes.
9. It is effective both in monotherapy and in complex treatment.
10. Original product, no generics, protected with the patents



The unique qualities of Miramistin® allow to use it in the therapy of various organ systems diseases, minimizing the risk of side-effects



APPROACHES TO THE INFECTIOUS DISEASES THERAPY OF THE SKIN

TRADITIONAL APPROACH WITH THE USE OF ANTIBIOTICS

Before the use of antibiotics, the main cause of pyoinflammatory diseases was thought to be hemolytic streptococcus. The use of antibiotics, to which streptococci are highly sensitive and almost do not acquire resistance, has led to a change in the etiological structure of the infection: the role of pathogenic antibiotic-resistant staphylococci and microbial associations has increased dramatically.

Other complications of local antibiotic treatment include the possibility of sensitization of the body, especially when using penicillin, streptomycin and other products.

Absorption of the products through the skin may occur when they are applied topically, which should be taken under serious consideration when prescribing pharmaceuticals with a potentially toxic effect.

There could also be disturbance in the composition of the normal microflora of the skin and its replacement by pathogenic microorganisms resistant to antibiotics. This may happen with the prolonged, local use of antibiotics.

There is a risk of spreading resistant forms of the pathogen.

MODERN APPROACH WITH THE USE OF THE PRODUCT INFLAMISTIN®

In order to improve the therapy, a new domestic product Inflammistin® was developed, the main active substance of which is Miramistin, which has a broad spectrum of antimicrobial activity, as well as immunomodulating properties.

To give the product anesthetic effect and enhance the reparative effect, trimecaine is additionally introduced, as well as D-panthenol, the concentrations of which are carefully selected for this purpose on a hydrophilic basis.

It has been proven by research that Inflammistin® has a pronounced antimicrobial effect against gram-positive, gram-negative bacteria, and fungi and have anesthetic and reparative qualities, surpassing in its activity domestic and foreign counterparts.



Location of the ointment production on the territory of the ECOBALTIC business park



Federal motorway Kaliningrad-Bezledy along the borders of the park



ECOBALTIC
BUSINESS PARK

Trigeneration

AB-Market

Filling workshop for Miramistin and Okomistin

BAGRATIONOVSK

Customs and logistics terminal SIRIUS



Workshops for ointments and substances

Sprayer manufacturing

Dart Plus


Catheter manufacturing

GDP warehouse



The Polish border (the international automobile border-crossing point "Bagrationovsk") is only few meters away

Production site requirements:
Area of the I stage building: 1 500 m²
Cadastral number of the land plot:
39:01:010219:99
(Kommunalnaya st., building 12,
Bagrationovsk, Kaliningrad Region)



Sanitation of the
production

1




2

Preparation of raw
and other materials

Injection of
pharmaceutical
substances into the basis

3



4

Homogenization of
ointments

Standardization of
finished products

5



6

Dispensing,
marking
and packaging
finished
products



ELECTRIC POWER

\$0,05/kWh

WATER SUPPLY

\$0,27
/m³

WATER DISPOSAL

\$0,13
/m³

GAS SUPPLY

\$75
/1 000 m³

LAND PLOT

\$60 000
/ha

OFFICE RENT

The price is negotiable

AVERAGE SALARY

\$6 360
per year

RENT OF PRODUCTION PREMISES

\$6/m²

The price for resources is calculated according to the state tariffs

The tariffs are changed 1-2 times a year

Calculation of variable expenses: monthly with metering devices

The prices do not include VAT



WE ARE READY TO SHARE
WITH YOU MORE!



Our address:

Kommunalnaya st, building 2, Bagrationovsk,
Kaliningrad Region, 238420



www.ecobaltic.com



+7 (4012) 310-369



info@ecobaltic.com